NEW YORK, July 23, 2026, 10:06 EDT
- Early intraday figures indicated Thermo Fisher stock rising roughly 10% to $578.85.
- Thermo Fisher Scientific reported a 10% rise in quarterly revenue, reaching $11.99 billion, while adjusted earnings were up 13%.
- Analytical Instruments accounted for 27.5% of incremental segment profit, while contributing 9.9% to incremental segment sales.
Shares of Thermo Fisher Scientific Inc. NYSE:TMO rose roughly 10% on Thursday after the company topped quarterly expectations and increased its profit outlook. U.S. cash markets were open. As of 9:52 a.m. EDT, the stock was trading at $578.85, according to initial intraday figures.
The main highlight was in Analytical Instruments, which saw revenue increase by 6.9%, as segment income surged 30.5%.
Company figures indicate the unit contributed 27.5% of additional segment profit, while accounting for just 9.9% of additional segment sales.
| Second-quarter segment | Revenue | Revenue growth | Segment margin | Margin change | Share of added segment profit |
|---|---|---|---|---|---|
| Life Sciences Solutions | $2.82 bln | 12.6% | 37.0% | +20 bps | 33.9% |
| Analytical Instruments | $1.85 bln | 6.9% | 23.0% | +420 bps | 27.5% |
| Specialty Diagnostics | $1.21 bln | 6.3% | 27.7% | +70 bps | 7.8% |
| Laboratory Products and Biopharma Services | $6.69 bln | 11.6% | 14.0% | +20 bps | 30.8% |
Data are compared to the previous year. Profit allocation references Thermo Fisher’s reported $360 million rise in segment income.
The data indicates instrument profit increased at a higher rate than sales. The margin widened by 420 basis points to 23.0%.
The group reported revenue of $11.99 billion, surpassing the average analyst forecast of $11.70 billion. Adjusted earnings came in at $6.03 per share, ahead of the $5.71 expected.
Organic growth was 5%, with acquisitions adding five percentage points and currency contributing one point. The reported overall figure was influenced by rounding.
Adjusted operating margin increased by 90 basis points to reach 22.8%. Free cash flow climbed 52%, totaling $1.68 billion.
Chief Executive Marc Casper stated that end markets “continue to strengthen.” He additionally pointed to ongoing increases in customer share. Thermo Fisher Scientific
Thermo Fisher updated its adjusted earnings outlook for 2026 to a range of $24.93 to $25.33 per share, up from the previous forecast of $24.64 to $25.12. The company’s revenue forecast was maintained at $47.4 billion to $48.1 billion.
Shares of Danaher Corp. NYSE:DHR advanced 4.3% on Thursday. The company reported a 3% increase in second-quarter core revenue, with its biotechnology segment posting 2.5% core growth. Danaher maintains its projection for full-year core growth in the range of 3% to 4%.
Vijay Kumar, an analyst at Evercore ISI, which is part of Evercore Inc. NYSE:EVR, described Danaher’s order postponement as “company-specific” and said it was “not reflective of the industry.” Reuters
Risks: Roughly half of Thermo Fisher’s reported growth stemmed from acquisitions. A drop in capital spending, changes in funding, currency fluctuations, or problems with integration could reduce the margin improvement.
The following assessment focuses on repeatability. Investors are set to monitor instrument margins as well as the contribution of organic growth.
